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CorrespondenceDNAMethylation
of Transcriptional Enhancers
and Cancer PredispositionPredisposition to common human dis-
eases is frequently associated with poly-
morphisms in distal control regions, also
known as gene enhancers. Li et al. (Li
et al., 2013) evaluated the relative contri-
butions of somatic and germline muta-
tions to intertumor gene expression
variation, with the aim of revealing links
between genomic regions associated
with cancer susceptibility and the expres-
sion of genes involved in cancer develop-
ment. The authors assessed the contribu-
tion ofDNAmethylation in gene promoters
to variation in intertumor gene expression
and found that 3.3% of this variation can
be attributed to methylation variation.
However, methylation could provide a
higher level of contribution to tumor het-
erogeneity and may further illuminate the
mechanism of cancer predisposition, if
the methylation of enhancer sites was
also taken into account. Enhancermethyl-
ation is drastically altered in cancers and
is closely related to altered expression
profiles of cancer genes (Aran et al.,
2013). Therefore, we have extended the
analysis of Li et al. to include methylation
sites in distal enhancers. The results indi-
cate that enhancer methylation status
data can contribute to the elucidation of
the regulatory circuits linking cancer risk
loci with expression profiles of cancer-
related genes.
We analyzed 390 estrogen receptor
(ER)-positive breast tumors for which
genomic methylation and expression
data were available at The Cancer
Genome Atlas (TCGA) website. To focus
on distal enhancers, we omitted from the
analysis methylation sites at <5 kb from
transcription start sites (TSSs). Using pub-
lished data on physical coupling between
distal regions and gene promoters in
MCF-7 cells (Li et al., 2012), we evaluated
the correlation of enhancer methylation
sites with the expression of the target
genes. Out of 10,361CpG site-gene pairs,
942 CpGs were significantly correlated
(R2 > 0.1, p < 0.05) with the expressionof 786 genes. In 73.2%of the genes, distal
methylation sites characterized expres-
sion levels better than promoter methyl-
ation (Figure 1A). Moreover, expression
variation of 49.2%of the geneswas exclu-
sively explained by enhancer methyla-
tions, whereas promoter methylation
showed no correlation with expression.
Overall, enhancer methylation explained
4.0%of intertumor gene expression varia-
tion in addition to the fraction explained by
promoter methylation.
We thus explored whether enhancer
methylation links cancer susceptibility
loci with cancer-driving mechanisms.
Indeed, we found that known breast-can-
cer-associated risk loci (genome-wide as-
sociation study [GWAS] catalog) are
significantly enriched (p < 0.00002) with
enhancer methylation sites correlated
with intertumor expression variation
(Figure 1B). Markedly, expression levels
of Cyclin D1 (CCND1), a prominent
breast cancer oncogene and a known
target of the estrogen receptor gene
ESR1, showed close relationships with
the methylation of five enhancer sites
within a breast-cancer-associated region
(Figure 1C). Furthermore, other key
drivers of breast cancer, including ESR1
itself and MAP3K1, were also correlated
with methylation sites located in enhancer
regions within breast cancer risk loci
(Figure 1D). We also assessed the rela-
tionships between DNA methylation and
estrogen receptor alpha (ER-a, the prod-
uct of the ESR1 gene, a key regulator of
breast cancer genes) binding levels in
MCF-7 cells, utilizing an independent
database (Fullwood et al., 2009). The re-
sults showed that ER-a binds enhancer
sites in a methylation-related manner
(Figure 1E), thus revealing a mechanistic
link between breast cancer enhancer ac-
tivity and DNA methylation levels. Hence,
the analysis of enhancer methylation re-
vealed regulatory connections between
breast cancer risk loci and genes driving
breast cancer development.CAlthough transgenerational transmis-
sion of methylation polymorphisms is
infrequent in the human genome, methyl-
ation analysis may be crucial for the un-
derstanding of germline-transmitted can-
cer predisposition. As shown by Li et al.,
the assessment of direct associations be-
tween polymorphic sequences and gene
expression only revealed mechanistic
links in a subset of the analyzed loci (6
out of 15). Elucidating the biology of the
remaining sites may require understand-
ing of genetic-epigenetic interactions
(Kim et al., 2013). Based on our findings
we suggest that enhancer sites contain
both sequence and methylation polymor-
phisms that define enhancer activity.
However, the correlation of polymorphic
sequences with gene expression is
apparently low, whereas the correlation
between expression and methylation is
considerably higher (Figure 1F). A recent
extensive analysis provides further exper-
imental support for the above model:
applying chromatin conformation cap-
turing and luciferase reporter assays, a
region upstream to the CCND1 gene
was shown to contain functional en-
hancers of the gene (French et al., 2013).
Sequence variants within these en-
hancers were associated with breast can-
cer risk, but, as in the Li et al. study,
showed no significant correlation with
CCND1 expression level, thus failing to
link risk sequence alleles with breast can-
cer mechanism. In contrast, our analysis
revealed a striking correlation of CCND1
expression level with methylation of the
very same enhancer region sites
(Figure 1C), thus providing the missing
link between this cancer risk locus and
mechanism. Additional risk loci in various
cancers and other common diseasesmay
also be explored using this approach.
We have shown that enhancer methyl-
ation accounts for a significant portion of
intertumor expression heterogeneity.
Many enhancer sites predict gene
expression levels better than promoter
methylation. Remarkably, cancer risk
loci are significantly enriched by expres-
sion-related methylation sites. The
analysis of these sites revealed novel
regulatory connections with drivers of
breast cancer development. We
suggest that exploration of distal DNA
methylation sites and their interactions
with germline polymorphisms canell 154, July 3, 2013 ª2013 Elsevier Inc. 11
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enhance understanding of the biology
behind cancer predisposition.
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